<DOC>
	<DOCNO>NCT02139280</DOCNO>
	<brief_summary>No prospective randomize trial evaluate efficacious dose cyclophosphamide mobilize autologous stem cell . We previously demonstrate time collection autologous hematopoietic stem cell 10-12 day follow one dose cyclophosphamide daily G-CSF ( granulocyte-colony stimulating factor ) .9 This prospective randomize trial design determine low dose cyclophosphamide ( 1.5 gm/m2 ) efficacious intermediate dose ( 3 gm/m2 ) , base cell number collect , number apheresis require resource utilization .</brief_summary>
	<brief_title>Cyclophosphamide Hematopoietic Stem Cell Mobilization Patients With Hematologic Malignancy</brief_title>
	<detailed_description>This prospective randomize trial design determine low dose cyclophosphamide ( 1.5 gm/m2 ) efficacious intermediate dose ( 3 gm/m2 ) , base cell number collect , number apheresis require resource utilization .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>All patient must pathologic diagnosis one follow malignancy : NonHodgkin 's Lymphoma , include B Tcell lymphoma Multiple Myeloma another plasma cell dyscrasia ( Waldenstrom , Amyloidosis ) The patient must approve transplant treat Transplant physician . This must patient 's FIRST mobilization attempt . Patients eligible autologous transplant plan within approximately 12 month time collection cell . Prior Treatment : No previous cytotoxic chemotherapy within 4 week prior initiation therapy . ( This include immunomodulatory drug ( IMiDs ) , proteasome inhibitor , monoclonal antibody steroid . ) No radiation within 4 week mobilization attempt . Age &gt; 18 , &lt; 75 year No significant comorbid medical psychiatric illness would significantly compromise patient 's clinical care chance survival . Informed consent must sign prior treatment . Patients must willingly consent informed procedure follow , nature therapy , alternative , potential benefit , side effect , risk discomfort . ( Human protection committee approval protocol consent form require . ) Medical , social , psychological factor would prevent patient receive cooperate full course therapy . Documented hypersensitivity drug use protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Hematopoietic</keyword>
	<keyword>Stem Cell</keyword>
	<keyword>Mobilization</keyword>
	<keyword>Hematologic Malignancy</keyword>
</DOC>